HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

July 20, 2043

Conditions
Ependymoma
Interventions
BIOLOGICAL

HER2 Specific CAR T Cell

HER2 CAR (Chimeric Antigen Receptor) T cells are T cells that have been genetically engineered to target the protein HER2 for the treatment of cancer.

Trial Locations (13)

10065

Memorial Sloan Kettering Cancer Center, New York

15224

Pittsburgh Children's Hospital of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

30329

Children's Healthcare of Atlanta, Atlanta

32608

University of Florida, Gainesville

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Texas Children's Cancer Center, Houston

80045

Children's Hospital Colorado, Aurora

90026

Children's Hospital Los Angeles, Los Angeles

02215

Dana Farber Cancer Institute, Boston

M5G1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Texas Children's Cancer Center

OTHER

collaborator

Baylor College of Medicine

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

American Lebanese Syrian Associated Charities

OTHER

lead

Pediatric Brain Tumor Consortium

NETWORK